



**THE FOUNDATION
FOR SECURE
MARKETS®**

#56893

Date: July 17, 2025

Subject: QTRX1 Options - Expiration Pricing Consideration

QTRX1 (adjusted Akoya Biosciences, Inc. options) will be subject to special pricing consideration in expiration processing on July 18, 2025. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of SLB1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

QTRX1

QTRX1 options are adjusted Akoya Biosciences, Inc. options, adjusted July 8, 2025 (see OCC Information Memo #56881). The deliverable of QTRX1 options is:

NEW DELIVERABLE

PER CONTRACT:

- 1) 14 Quanterix Corporation (QTRX) Common Shares
- 2) Cash in lieu of 0.7 fractional QTRX Shares
- 3) \$37.00 Cash

As of July 17, 2025, the QTRX Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a QTRX1 price for use in expiration processing, OCC will use the following formula:

$$\text{QTRX1} = 0.147 (\text{QTRX}) + 0.37$$

For example, if QTRX closes at 5.66, the QTRX1 price would be:

$$\text{QTRX1} = 0.147 (5.66) + 0.37 = 1.20$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the merger.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.